logo

Immunogen Inc (IMGN)



Trade IMGN now with
  Date
  Headline
1/4/2023 6:32:36 AM ImmunoGen Appoints Michael Vasconcelles, As EVP, Research, Development, And Medical Affairs
12/9/2022 6:35:12 AM ImmunoGen Announces Clinical Collaboration With Gilead To Evaluate Pivekimab Sunirine With Magrolimab In R/R AML
11/21/2022 6:33:23 AM ImmunoGen Names Daniel Char SVP And Chief Legal Officer
8/31/2022 6:36:32 AM ImmunoGen Updates On CADENZA Study Of Pivekimab Sunirine In Frontline Blastic Plasmacytoid Dendritic Cell Neoplasm
7/29/2022 6:37:11 AM ImmunoGen Q2 Total Revenues $14.2 Mln Vs. $16.9 Mln Prior Year
6/13/2022 6:36:35 AM ImmunoGen Collaborates With Oxford BioTherapeutics To Develop Novel Antibody-Drug Conjugates
5/23/2022 6:34:26 AM ImmunoGen: FDA Accepts BLA For Mirvetuximab Soravtansine In Ovarian Cancer With Priority Review
5/6/2022 6:38:15 AM ImmunoGen Q1 Net Loss $24.1 Mln Or $0.10/Shr Vs Loss Of $34.1 Mln Or $0.17/Shr Last Year
3/29/2022 6:50:26 AM ImmunoGen Submits BLA To FDA For Mirvetuximab Soravtansine In Ovarian Cancer
3/10/2022 6:35:42 AM ImmunoGen To Present Full Results From SORAYA Trial Of Mirvetuximab Soravtansine In Ovarian Cancer